MXPA05000832A - Metodos de diagnosticar y tratar pre-eclampsia o eclampsia. - Google Patents

Metodos de diagnosticar y tratar pre-eclampsia o eclampsia.

Info

Publication number
MXPA05000832A
MXPA05000832A MXPA05000832A MXPA05000832A MXPA05000832A MX PA05000832 A MXPA05000832 A MX PA05000832A MX PA05000832 A MXPA05000832 A MX PA05000832A MX PA05000832 A MXPA05000832 A MX PA05000832A MX PA05000832 A MXPA05000832 A MX PA05000832A
Authority
MX
Mexico
Prior art keywords
eclampsia
methods
diagnosing
clamp
treating pre
Prior art date
Application number
MXPA05000832A
Other languages
English (en)
Inventor
Vikas P Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of MXPA05000832A publication Critical patent/MXPA05000832A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Un producto alimenticio para bocadillo comprende un centro conformado de una masa coherente de huevos revueltos envuelta en un recubrimiento de rebozado empanizado. En un sistema incinerador, rejillas secadoras con control de temperatura proporcionado por el vapor bifasico. Los desechos o granel muy mojados que entran en un incinerador se asientan sobre una rejilla antes de caer sobre el piso del hogar por debajo. Esto elimina los hidrocarburos volatiles y permiten la sequia. La rejilla .puede tambien proporcionar el aire de combustion. El proceso de sequia causa que el contenido de humedad de los desechos caiga de bajo de 50 por ciento, cuando la combustion puede ocurrir. El vapor bifasico pasa a traves de canales separados en la rejilla para controlar su temperatura. El gas que contiene oxigeno proveniente de la rejilla hacia la camara de combustion puede contener los productos gaseosos de la combustion, o el gas del humero, con o sin aire para hacer uso del calor y el contenido de humedad del anterior. Cuando el gas del humero contiene clorina, su temperatura deberia, por medio de la adicion del aire enfriado, caer dentro del nivel del 204degree C a 399degree C. para evitar la corrosion causada por la clorina, los sopladores que propulsan el gas del humero deben permanecer completamente fuera de la corriente de gas o deben entrar en contacto con el gas del humero solamente despues de que se hayan enfriado a este nivel de temperatura. Para los desechos destrozados o en particulas, una segunda rejilla escalonada por debajo de la primera permite que los desechos se detengan alli durante el suficiente espacio de tiempo para que el material se seque y pierda sus hidrocarburos volatiles. Un cargador entra al incinerador para empujar los desechos sobre la tejilla y para limitar el espesor de los desechos de modo que el gas de la rejilla pueda penetrarlos.
MXPA05000832A 2002-07-19 2003-07-21 Metodos de diagnosticar y tratar pre-eclampsia o eclampsia. MXPA05000832A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39748102P 2002-07-19 2002-07-19
US45179603P 2003-03-03 2003-03-03
US46739003P 2003-05-02 2003-05-02
PCT/US2003/022892 WO2004008946A2 (en) 2002-07-19 2003-07-21 Methods of diagnosing and treating pre-eclampsia or clamp

Publications (1)

Publication Number Publication Date
MXPA05000832A true MXPA05000832A (es) 2005-10-19

Family

ID=30773520

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05000832A MXPA05000832A (es) 2002-07-19 2003-07-21 Metodos de diagnosticar y tratar pre-eclampsia o eclampsia.

Country Status (19)

Country Link
US (2) US7407659B2 (es)
EP (3) EP2305301B1 (es)
JP (2) JP5650876B2 (es)
KR (1) KR101215701B1 (es)
CN (1) CN1777443B (es)
AP (1) AP2005003230A0 (es)
AU (2) AU2003265294B8 (es)
BR (1) BRPI0312818B8 (es)
CA (2) CA2496253C (es)
DK (3) DK1575416T3 (es)
EA (1) EA200500232A1 (es)
EC (1) ECSP055608A (es)
ES (3) ES2534926T3 (es)
HK (3) HK1085368A1 (es)
IL (2) IL166393A (es)
MX (1) MXPA05000832A (es)
OA (1) OA12890A (es)
PT (3) PT2305301E (es)
WO (1) WO2004008946A2 (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
ES2534926T3 (es) * 2002-07-19 2015-04-30 Beth Israel Deaconess Medical Center Métodos para tratar la preeclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
ATE394679T1 (de) 2002-11-16 2008-05-15 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
WO2005017192A2 (en) * 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
US8273383B2 (en) * 2004-05-04 2012-09-25 Children's Medical Center Corporation Methods and compositions for treatment of preeclampsia
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
KR20130119506A (ko) 2004-09-24 2013-10-31 베스 이스라엘 데코니스 메디칼 센터 임신성 합병증의 진단 및 치료 방법
DE102004051847B4 (de) 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
WO2007053161A2 (en) 2004-12-15 2007-05-10 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
WO2006069373A2 (en) 2004-12-21 2006-06-29 Yale University Diagnosis of preeclampsia
US20060153835A1 (en) * 2005-01-12 2006-07-13 Smith Henry J Treatment of pre-eclampsia in pregnant women using targeted apheresis
AU2006226891A1 (en) * 2005-03-24 2006-09-28 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
US20090197794A1 (en) * 2005-07-13 2009-08-06 Aird William C Methods of Diagnosing and Treating an Inflammatory Response
US8329175B2 (en) 2005-08-26 2012-12-11 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
US20070111326A1 (en) * 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US20080071151A1 (en) * 2006-06-30 2008-03-20 Sogin David C Method and Apparatus for Diagnosing Pre-eclampsia
US20080003230A1 (en) 2006-07-03 2008-01-03 Adair Charles D Composition for modulating the expression of cell adhesion molecules
DE602006015964D1 (de) * 2006-09-20 2010-09-16 Roche Diagnostics Gmbh Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion
CA2670134A1 (en) * 2006-11-21 2008-08-28 Beth Israel Deaconess Medical Center Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications
ATE547523T1 (de) * 2006-12-20 2012-03-15 Yissum Res Dev Co Vegfr-varianten und deren verwendung bei der diagnose und behandlung von mit schwangerschaft assoziierten medizinischen leiden
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
RU2010133157A (ru) 2008-01-07 2012-02-20 Орто-Клиникал Дайэгностикс, Инк. (Us) Определение комплекса sflt-1:ангиогенный фактор
EP2245180B1 (en) * 2008-01-25 2014-06-18 PerkinElmer Health Sciences, Inc. Methods for determining the risk of prenatal complications
CN110187119B (zh) * 2008-10-31 2022-07-29 耶鲁大学 子痫前期检测和治疗的方法和组合物
WO2010065437A1 (en) 2008-12-03 2010-06-10 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US8349325B2 (en) * 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
US20100247650A1 (en) * 2009-03-31 2010-09-30 Smith Henry J Treatment for pre-eclampsia in pregnant women using targeted apheresis
WO2011036429A1 (en) * 2009-09-25 2011-03-31 The University Of Bristol Detection of risk of pre-eclampsia
US8530150B2 (en) * 2009-09-25 2013-09-10 The University Of Bristol Detection of risk of pre-eclampsia
EP2543729B1 (en) 2010-03-04 2017-11-01 Masaru Okabe Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor
DE102010013555A1 (de) 2010-03-31 2011-10-06 Christian Hamm Verwendung der Biomarker sFlt und PIGF in der Diagnose und Therapie der pulmonalen Hypertonie
EP3248946B1 (en) 2010-05-14 2021-02-24 Beth Israel Deaconess Medical Center, Inc. Extracorporeal devices and methods of treating complications of pregnancy
KR20130091750A (ko) * 2010-07-19 2013-08-19 에프. 호프만-라 로슈 아게 유방암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커
KR20130091746A (ko) * 2010-07-19 2013-08-19 에프. 호프만-라 로슈 아게 췌장암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커
WO2012109282A2 (en) 2011-02-07 2012-08-16 Agamin Pharmaceuticals, Llc Methods and systems for treating or preventing pregnancy-related hypertensive disorders
EP2490027A1 (en) * 2011-02-15 2012-08-22 Roche Diagnostics GmbH Means and methods for diagnosing pregnancy complications based on GDF-15 and PlGF/sFlt1
RU2462765C1 (ru) * 2011-04-25 2012-09-27 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ коррекции эндотелиальной дисфункции дистантным прекондиционированием при adma-подобной модели гестоза
RU2462766C1 (ru) * 2011-04-25 2012-09-27 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ коррекции эндотелиальной дисфункции рекомбинантным эритропоэтином при adma-подобной модели гестоза
RU2460148C1 (ru) * 2011-04-25 2012-08-27 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ коррекции нарушения микроциркуляции в плаценте при adma-подобной модели гестоза
RU2466462C1 (ru) * 2011-04-25 2012-11-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ коррекции нарушения микроциркуляции в плаценте рекомбинантным эритропоэтином при adma-подобной модели гестоза
AU2012294814A1 (en) 2011-08-05 2014-02-27 Research Development Foundation Improved methods and compositions for modulation of Olfml3 mediated angiogenesis
CN103917875B (zh) 2011-11-09 2016-11-09 霍夫曼-拉罗奇有限公司 SFlt-1或Endoglin/PlGF的比例动态用作危急的先兆子痫和/或HELLP综合征的指示物
RU2673074C2 (ru) * 2011-12-15 2018-11-22 Майкартис Н.В. Биомаркеры и параметры для определения гипертензивных расстройств при беременности
RU2507594C2 (ru) * 2012-03-07 2014-02-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Способ коррекции эндотелиальной дисфункции при adma-подобной модели гестоза в эксперименте
RU2507595C2 (ru) * 2012-03-07 2014-02-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Способ коррекции эндотелиальной дисфункции азитромицином при adma-подобной модели гестоза в эксперименте
RU2483311C1 (ru) * 2012-06-15 2013-05-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздравсоцразви Способ диагностики преэклампсии у беременных с хронической артериальной гипертензией
KR101996123B1 (ko) 2012-06-27 2019-07-03 에프. 호프만-라 로슈 아게 특정 시기 내에 임신중독증의 개시를 배제하기 위한 sFlt-1/PlGF 또는 엔도글린/PlGF 비의 적용 수단 및 방법
EP2706359A1 (en) 2012-09-07 2014-03-12 Roche Diagniostics GmbH Means and methods applying sFlt-1/PlGF or Endoglin/PlGF ratio to rule-out onset of preeclampsia within a certain time period
KR101297886B1 (ko) * 2012-10-02 2013-08-19 인제대학교 산학협력단 자간전증의 조기 진단 및 예후 평가 방법
DK2912064T3 (da) 2012-10-24 2019-07-22 Res Found Dev Jam-c-antistoffer og fremgangsmåder til behandling af cancer
EP3036005A4 (en) 2013-08-21 2017-04-26 The Board Of Regents Of The University Of Texas System Compositions and methods for targeting connexin hemichannels
CN105917233B (zh) * 2014-01-24 2018-07-03 豪夫迈·罗氏有限公司 产后hellp综合征、产后子痫或产后子痫前期的预测
RU2543359C1 (ru) * 2014-03-11 2015-02-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции эндотелиальной дисфункуии фармакологическим прекондиционированием никорандилом при adma-подобной модели гестоза в эксперименте
JP6697394B2 (ja) 2014-04-10 2020-05-20 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 異常折り畳みタンパク質を検出するための方法および組成物
JP6822412B2 (ja) * 2015-02-18 2021-01-27 アストン ユニヴァーシティー 妊娠高血圧腎症のための診断アッセイ及び治療
GB201504772D0 (en) 2015-03-20 2015-05-06 Univ Aston Preeclampsia
CA2980337A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Oligonucleotide compounds for targeting huntingtin mrna
EP3995581A3 (en) 2015-04-03 2022-10-26 University of Massachusetts Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
US10738123B2 (en) * 2015-04-07 2020-08-11 Shire Human Genetic Therapies, Inc. Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
MX2017012831A (es) * 2015-04-07 2018-05-04 Shire Human Genetic Therapies Anticuerpos anti receptor del factor de crecimiento endotelial vascular 1 (flt-1) en el tratamiento de displasia broncopulmonar.
JP6675687B2 (ja) * 2015-05-29 2020-04-01 国立大学法人名古屋大学 尿中ＶＥＧＦ−Ａ１６５ｂを指標とした腎機能の検査方法及び検査装置、腎機能の検査装置として機能させるためのプログラム及び記録媒体
FR3037657B1 (fr) * 2015-06-22 2017-06-23 Univ Rouen Centre Hospitalier Methode de diagnostic des troubles causes par l'alcoolisation foetale
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES
EP3909983A1 (en) 2015-12-02 2021-11-17 STCube & Co. Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
US10511462B2 (en) * 2016-01-06 2019-12-17 Apple Inc. DC offset cancelation for wireless communications
JP2019503394A (ja) 2016-01-31 2019-02-07 ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 分岐オリゴヌクレオチド
US10889637B2 (en) 2016-02-26 2021-01-12 The Board Of Regents Of The University Of Texas System Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
WO2017148854A1 (en) 2016-02-29 2017-09-08 Roche Diagnostics Gmbh Igfbp-7 as a marker in preeclampsia
US11660352B2 (en) 2016-03-29 2023-05-30 Stcube, Inc. Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
KR101916652B1 (ko) * 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
KR20190031299A (ko) 2016-07-20 2019-03-25 주식회사 에스티큐브 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
US11753638B2 (en) 2016-08-12 2023-09-12 University Of Massachusetts Conjugated oligonucleotides
CN107884570A (zh) * 2016-09-29 2018-04-06 韦彦余 一种孕妇先兆子痫检测试剂盒
JP2020522512A (ja) 2017-05-31 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
AU2018331400A1 (en) 2017-09-13 2020-04-02 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
GB2581619A (en) 2017-09-15 2020-08-26 Univ California Inhibition of aminoacylase 3 (AA3) in the treatment of cancer
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
CN114729045A (zh) 2019-09-26 2022-07-08 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
EP4041768A1 (en) 2019-10-09 2022-08-17 StCube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
KR102435297B1 (ko) * 2020-07-21 2022-08-22 부산대학교 산학협력단 임신중독증 조기진단용 바이오마커 조성물 및 이를 이용한 진단방법
BR112023026862A2 (pt) 2021-06-23 2024-03-05 Beth Israel Deaconess Medical Ct Inc Compostos de oligonucleotídeos anti-flt1 otimizados para tratamento de pré-eclâmpsia e outros distúrbios angiogênicos
WO2023104975A1 (en) 2021-12-08 2023-06-15 B.R.A.H.M.S Gmbh Biomarkers for prognosis of early onset preeclampsia

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
WO1989009825A1 (en) 1988-04-16 1989-10-19 Celltech Limited Method for producing recombinant dna proteins
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5238819A (en) 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US6410322B1 (en) 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5543138A (en) 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
GB9512994D0 (en) * 1995-06-26 1995-08-30 Brf International Method for quantitative measurement of an enzyme linked immunosorbent assay
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6399585B1 (en) 1996-05-15 2002-06-04 Janet E. Larson In Utero treatment of CFTR-related deficiencies
EP0951298A1 (en) 1996-12-23 1999-10-27 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
US20030114407A1 (en) 2001-12-06 2003-06-19 Monia Brett P. Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression
US7030083B2 (en) 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
EP1417971A3 (en) * 1998-09-09 2004-06-30 Scios Inc. Use of an angiogenic factor for the treatment of microvascular angiopathies
US6677300B1 (en) 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
US6245577B1 (en) * 1998-09-11 2001-06-12 Midland Bioproducts Corporation IgG antibody testing method
EP1016726A1 (en) 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
GB0026823D0 (en) 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
WO2002070535A1 (en) 2001-03-01 2002-09-12 Isis Pharmaceuticals, Inc. Antisense modulation of recql5 expression
ES2534926T3 (es) * 2002-07-19 2015-04-30 Beth Israel Deaconess Medical Center Métodos para tratar la preeclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
WO2005017192A2 (en) 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
US7344892B2 (en) 2003-09-23 2008-03-18 Beth Israel Deaconess Medical Center, Inc. Screening for gestational disorders
WO2006069373A2 (en) 2004-12-21 2006-06-29 Yale University Diagnosis of preeclampsia
US7335562B2 (en) * 2005-10-24 2008-02-26 Kabushiki Kaisha Toshiba Method of manufacturing semiconductor device

Also Published As

Publication number Publication date
KR101215701B1 (ko) 2012-12-26
US20040126828A1 (en) 2004-07-01
CA2922031A1 (en) 2004-01-29
JP2006511615A (ja) 2006-04-06
HK1156233A1 (en) 2012-06-08
DK2305301T3 (en) 2015-04-13
AU2003265294A1 (en) 2004-02-09
JP5650876B2 (ja) 2015-01-07
CN1777443A (zh) 2006-05-24
EP1575416A2 (en) 2005-09-21
EP2305301A3 (en) 2011-06-22
AU2009202176B2 (en) 2012-12-06
EP2308507A2 (en) 2011-04-13
HK1085368A1 (en) 2006-08-25
ES2534926T3 (es) 2015-04-30
CA2496253A1 (en) 2004-01-29
JP2014193920A (ja) 2014-10-09
DK2308507T3 (da) 2015-04-20
CA2922031C (en) 2020-12-15
BRPI0312818B1 (pt) 2019-08-20
AU2003265294B8 (en) 2009-06-25
WO2004008946A2 (en) 2004-01-29
HK1156521A1 (en) 2012-06-15
US20090004669A1 (en) 2009-01-01
EA200500232A1 (ru) 2005-12-29
AU2003265294B2 (en) 2009-06-04
ES2440651T3 (es) 2014-01-29
EP2308507A3 (en) 2011-06-22
EP2308507B1 (en) 2015-01-14
EP1575416A4 (en) 2007-09-05
PT2308507E (pt) 2015-05-11
ECSP055608A (es) 2006-03-01
IL233205B (en) 2020-04-30
US7407659B2 (en) 2008-08-05
EP2305301B1 (en) 2015-01-07
BR0312818A (pt) 2007-06-26
BRPI0312818B8 (pt) 2021-05-25
PT1575416E (pt) 2014-01-08
WO2004008946A3 (en) 2006-01-05
AP2005003230A0 (en) 2005-03-31
AU2009202176A1 (en) 2009-06-18
CA2496253C (en) 2016-05-10
IL166393A (en) 2015-06-30
CN1777443B (zh) 2010-06-23
IL233205A0 (en) 2014-07-31
PT2305301E (pt) 2015-04-21
KR20060002008A (ko) 2006-01-06
OA12890A (en) 2006-10-13
DK1575416T3 (da) 2014-01-13
EP1575416B1 (en) 2013-10-02
EP2305301A2 (en) 2011-04-06
ES2534294T3 (es) 2015-04-21
US7947449B2 (en) 2011-05-24
JP5973496B2 (ja) 2016-08-23
IL166393A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
MXPA05000832A (es) Metodos de diagnosticar y tratar pre-eclampsia o eclampsia.
MY169308A (en) Treatment of tnf? related disorders
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
DK1682074T3 (da) Præparater og fremgangsmåder til sund graviditet
HK1145692A1 (zh) 人血管生成素- 的特異結合劑
ATE541847T1 (de) Pyrazolopyrimidine als natriumkanalblocker
EP1451160A4 (en) PYRAZOLE-AMIDES AND -SULFONAMIDES
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
TW200518755A (en) Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
MXPA05012880A (es) Inhibidores de complemento.
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
TNSN04015A1 (en) Combination therapy for the treatment of cancer
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
WO2006060787A3 (en) Delaying or preventing onset of multiple sclerosis
WO2003075953A3 (en) Immunomodulatory polymeric antigens for treating inflammatory pathogies
ATE495794T1 (de) Metallionenchelatoren und ihre therapeutische verwendung
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
PT808172E (pt) Combinacao de inibidor da enzima de conversao da angiotensina e de antagonista de aldosterona para o tratamento de hipertrofia ventricular
TNSN05015A1 (en) Methods of diagnosing and treating pre-eclampsia or eclampsia
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
ZA200203985B (en) Therapies for tissue damage resulting from ischemia.
AU2003282035A1 (en) Modulation of s6 kinase activity for the treatment of obestiy
NO20004363L (no) Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontrollforstyrrelser og autisme

Legal Events

Date Code Title Description
FG Grant or registration